Alberto Bardelli, Ph.D.
University of Torino, School of Medicine
It is now evident that the ultimate goal of delivering the right drug to the right patient (personalized medicine) requires a detailed understanding of the genomic alterations of individual tumors. We study colorectal cancer as a model system to analyze how mutations in tumor DNA are linked to responses to cancer drugs. Our goal is to define genotype-pharmacological relationship that can translate into far more educated choices for the treatment of patients, leading to greater therapeutic benefit, while at the same time reducing the toxicity of non effective cancer drugs.